Precision medicine is reshaping medical research and clinical practice. At this Open Thinking event on May 5, discover how scientists and physicians from industry and academia envision the impact of risk prediction in cardiovascular medicine.
Sponsored by the Center for Technology Innovation & Commercialization of Wake Forest Innovations, Open Thinking brings industry experts into conversation with researchers and clinicians at Wake Forest Baptist Medical Center to share perspectives on a leading topic in medical innovation.
This event, Open Thinking: Precision Cardiology, offers two opportunities to engage with experts from Ferrer inCode, an international molecular diagnostics and precision medicine company. The title of their talk is Latest Insights: The opportunity to prevent cardiovascular events and genetic risk scoring.
Precision Cardiology in the Clinic
Cardiovascular Medicine Grand Rounds
7:30 am – 8:15 am
Medical School Board Room
Coy Carpenter Library
Precision Cardiology in Research
Lunch & Learn
12 pm – 1:30 pm
Registration is requested. Lunch is complimentary.
Parking in the Innovation Quarter
Not located in Wake Forest Innovation Quarter? To attend the Lunch & Learn at Wake Downtown, take the shuttle service from Eden Terrace (Hanes Building) to the Wake Forest Biotech Place/525@vine/Medical Education Building stop in the Innovation Quarter. Check the van services schedule for departure times.
Limited visitor parking is also available in the P8 lot located off North Research Parkway between 5th Street and 7th Street.
About the Speakers
Robert Jenkins, PhD, MBA, Ferrer inCode
Robert Jenkins, PhD, MBA, earned his doctorate in molecular biology from Cambridge University and has held many positions in the management of science and research activity and business development. His specific interests include molecular diagnostics and genomics, point-of-care testing and hemostasis. Prior to joining Ferrer inCode five years ago as senior vice president of business development, he was worldwide head of business development for Instrumentation Laboratory and Inova Diagnostics.
Eduardo Salas, MD, PhD, Ferrer inCode
Eduardo Salas, MD, PhD, received his medical and doctorate degrees from the University de Cantabria in Spain. He has many years of clinical and research experience in endocrinology and cardiology at the Marqués de Valdecilla University Hospital. Salas has extensive leadership experience in pharmaceutical industry research and development and is currently chief scientific officer of Gendiag and Ferrer inCode. His responsibilities include the development of intellectual property pipeline and the direction of clinical studies. He also serves as assistant professor in a university masters’ program in translational medicine, molecular biotechnology and leadership and management in science and innovation.